IMPLANET Revenue Soars 33% on Global Expansion and Robotics Push

BORDEAUX, France – January 13, 2026 – Medical technology company IMPLANET has announced a landmark year, reporting full-year 2025 revenues of €12.5 million, a sharp 33% increase over the previous year. The robust performance, marking the company’s sixth consecutive quarter of sustained growth, signals that its strategic pivot towards product diversification and aggressive international expansion is yielding significant results.

The growth was driven by strong performances across both its core spinal implant business and its rapidly expanding medical equipment distribution arm. This dual-engine approach has allowed the company to fortify its market position and lay the groundwork for a strategic entry into the high-growth surgical robotics sector.

“We delivered a very strong commercial performance in 2025, with revenue of €12.5 million, representing +33% growth compared with the same period last year, thereby confirming the relevance of the development model we have been implementing for the past two years,” stated Ludovic Lastennet, CEO of IMPLANET. “Building on six consecutive quarters of sustained growth, we are firmly confident in the outlook for the coming quarters.”

Global Ambitions Fueling Growth

A deep dive into the numbers reveals a successful international strategy. While revenue in its home market of France saw a respectable 8% increase to €4.44 million, the company’s most impressive gains came from abroad. Revenue in the United States surged by 49% to €3.84 million, a critical achievement in the world's largest and most competitive medical device market. This growth was largely propelled by the company's medical equipment distribution business.

Even more striking was the 55% revenue explosion in the “Rest of World” category, which climbed to €4.20 million. A significant contributor to this success was IMPLANET’s successful entry into the Chinese market. Following regulatory approval from China's National Medical Products Administration (formerly CFDA) for its innovative JAZZ® implant range, the company recorded its first surgical procedures and initial deliveries in the country, totaling €0.52 million since July 2025. This beachhead in China, the world's largest spine market by volume, is bolstered by a crucial strategic partnership with Sanyou Medical, the country's second-largest medical device manufacturer.

Further diversifying its revenue streams, IMPLANET's medical equipment distribution business (SMTP) posted a remarkable 66% growth, reaching €3.91 million. This segment now accounts for 31% of the company's total revenue, up from a smaller fraction in previous years. The growth is attributed to the successful rollout of the Olea ultrasonic scalpel and an exclusive U.S. distribution partnership with elliquence for endoscopic spine surgery equipment.

Innovating the Future of Spinal Surgery

At the core of IMPLANET's portfolio is its technology for spinal pathologies. The company’s spine implant revenue grew a healthy 22% in 2025 to €8.57 million. This was driven by its flagship JAZZ® braided implant technology and the new Jazz Spinal System™ (JSS), a hybrid posterior fixation system that combines the JAZZ® band with a comprehensive pedicle screw solution.

The company is now poised for an accelerated push in the United States after its entire JSS range received 510(k) clearance from the Food and Drug Administration (FDA). This regulatory milestone opens the door for a full commercial launch across the U.S., a key focus for the company moving forward.

Perhaps the most forward-looking aspect of IMPLANET's strategy is its capital-efficient entry into the surgical robotics market. Rather than investing heavily in in-house R&D to compete with giants like Medtronic and Globus Medical, IMPLANET has forged strategic partnerships. The company signed an exclusive distribution agreement with TINAVI Medical Technologies for its TiRobot® system, a sophisticated platform for robotic-assisted spine surgery. It has also partnered with 8i Robotics Inc. for the clinical evaluation of a new surgeon-assisted robotic system.

This two-pronged approach allows IMPLANET to immediately add advanced robotic solutions to its commercial offering, positioning it as a more comprehensive partner for surgeons and hospitals without the associated development costs and timelines.

A Fortified Financial Position

To fuel these ambitious growth plans, IMPLANET has shored up its financial standing. The company ended 2025 with a cash position of €3.03 million. This was significantly boosted by a successful capital increase announced in November 2025, which raised €4.49 million. According to the company, these funds are sufficient to cover its operating financing needs for the next twelve months based on current forecasts and growth plans.

While the company continues to invest heavily in expansion and is not yet profitable—reporting an operating loss of -€2.14 million in the first half of 2025—its improving financial results and strategic execution are building a foundation for long-term stability. The financial partnership with Sanyou Medical, which has already provided a loan guarantee, offers an additional layer of support.

With regulatory hurdles cleared in key markets, a diversifying product portfolio that now includes robotics, and a strengthened balance sheet, IMPLANET appears well-positioned to continue its growth trajectory. The company's focus now shifts to executing its commercial strategy, particularly in the lucrative U.S. market, and capitalizing on its new technological and geographical footholds to carve out a larger share of the global orthopedic industry.